

Sixteen (trial 0020) and four (trial 0021) patients provided blood samples at intervals over 28 days for full PK profiles after the first injection. Thereafter monthly samples were obtained from 27 patients (trial 0020) and from all patients in trial 0021 (n = 194), and continued for up to 30 months (i.e., 30 injections) after the first dose.

The shape of the observed plasma FAS profiles following i.m. injection of the LA formulation was very similar in both studies. Gmean trough plasma concentrations increased slightly after the first injection from 2.4 ng/ml and 2.6 ng/ml, increasing to 6.5 ng/ml and 6.2 ng/ml in trials 20 and 21 respectively, reaching steady state after approximately three to six doses. Steady-state plasma FAS exposures ( $AUC_{0-\infty}$ ), was reached in 3–6 doses and predicted according to a structural model were very similar for both studies (trial 0020: 336 ng.d/ml, trial 0021: 294 ng.d/ml), and, by comparison with single dose data, represents approximately two-fold accumulation. The repeated i.m. injections were well tolerated in both studies. The results of this study show that 5 ml and 2.5 ml injections of FAS 250 mg are equally effective in maintaining plasma FAS levels in the therapeutic range for at least 30 months, and support the use of either dosing regimen in the clinical setting.

#### **O-24. ICI 182,780 ('FASLODEX'<sup>TM</sup>) IS AT LEAST AS EFFECTIVE AS ANATROZOLE (ARIMIDEX'<sup>TM</sup>) IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER PROGRESSING ON PRIOR ENDOCRINE TREATMENT**

A. Howell, J.F.R. Robertson, J. Quaresma Albano, A. Aschermannova, L. Mauriac, U.R. Kleeberg, I. Bergote, B. Erikstein, A. Webster, C. Morris. *Christie Hospital Manchester, UK, City Hospital Nottingham, UK, Instituto Portugues De Oncologia, Nova Ves Plod Plesi, Czech Republic, Institut Bergonie, Bordeaux, France, Hamburg, Germany, University Hospital Leuven, Belgium, Norwegian Radium Hospital, Oslo, AstraZeneca UK*

ICI 182,780 ('Faslodex'<sup>TM</sup>) (FAS) is the first of a new class of anti-oestrogen: an Estrogen Receptor Downregulator. We report the results of two, randomised, multicentre, parallel-group trials, (0020 European and 0021 North American) comparing the efficacy and tolerability of a monthly intramuscular injection of 250 mg FAS with that of a daily oral administration of anastrozole (Arimidex'<sup>TM</sup>) (AN) 1 mg in post-menopausal (PM) women with advanced breast cancer (ABC) progressing on prior endocrine treatment. Primary endpoint was time to progression (TTP). Secondary endpoints included objective response (OR) rate, duration of response (DOR), and tolerability. Patients were recruited from 1997 to 1999 and randomly assigned to either FAS or AN. The median follow-up duration was 14.4 months (mo) for study 0020 and 16.8 months for study 0021, with disease progression in 83% of randomised patients. Both drugs had similar tolerability profiles and were well tolerated. The incidence of withdrawals due to a drug-related adverse event was 0.9% for FAS and 1.2%

for AN. Data from all major efficacy endpoints are shown in Table.

	0020		0021	
	FAS	AN	FAS	AN
Median TTP (months)	5.5	5.1	5.4	3.4
OR (CR + PR)	20.7%	15.7%	17.5%	17.5%
Clinical Benefit Rates	44.6%	45%	42.2	36.1
Median DOR	14.3	14.0	19.3	10.5

This is the first anti-oestrogen, which is at least as effective as the new generation aromatase inhibitor, AN in PM women with ABC and is especially noteworthy since most patients had had prior tamoxifen treatment. FAS will be a valuable additional treatment option for ABC in these patients.

#### **O-25. CORRELATION OF IMMUNOHISTOCHEMISTRY (IHC) AND GENE MICROARRAY ANALYSIS OF BREAST BIOPSIES FROM A PREOPERATIVE ENDOCRINE THERAPY TRIAL**

A. Coop, M. Dressman, C. Lavedan, B. Singh, A. Llombart-Cussac, W.R. Miller, F. Janicke, L. Mauriac, D.B. Evans, M. Borgs, M. Polymeropoulos. *Lombardi Cancer Center, USA; Instituto Valesciano de Oncologia Spain, Western General Hospital, Edinburgh, UK, Frauen-und Poliklinik, Hamburg, Germany; Institut Bergonie Bordeaux, France; Novartis AG*

**Background:** IHC is used to assign predictive/prognostic marker status in breast cancer, but is limited by antibody availability. Microarray analysis rapidly evaluates expression of large numbers of genes and is a potentially efficient screen for identifying novel markers. However, for this purpose microarray and IHC assignment of standard markers must correlate.

**Methods:** Breast biopsies were collected before and after pre-operative endocrine therapy from patients in a phase III trial comparing letrozole with tamoxifen. RNA was extracted from non-dissected frozen biopsies and converted to cRNA. Estrogen receptor (ER) and trefoil factor 1 (PS2) expression was determined with the FL Affymetrix array. ER and PS2 IHC were performed using standard methodology. Protein expression was scored by the Allred method (intensity + proportion); a score > 3 was considered positive.

**Results:** Expression profiles determined by array or IHC were scored as present and absent and expression levels were also recorded. IHC and gene expression profiles were available for 29 biopsies (17 pre- and 12 post-treatment) from 24 patients. The presence or absence of ER determined by array was concordant with IHC scored by the Allred method in 100% (29/29) of biopsies, however levels of ER mRNA measured by array did not correlate with IHC protein levels ( $r = 0.267$ ,  $p = 0.161$ ). Presence or absence of PS2 determined by array and IHC was concordant in 75% (21/28, 1 assay failure) of biopsies. A significant correla-